Differential time dependency of antiproliferative and apoptotic effects of taxol in human prostate tumors

Urologic Oncology

Volumn 3, Issue 1, 1997, Pages 11-17

  Chen, Chiung Tong ^a   Au, Jessie L S ^a   Gan, Yuebo ^a   Wientjes, M Guillaume ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Pharmacodynamics; Prostate cancer; Taxol

Indexed keywords

PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CYTOTOXICITY; CYTOTOXICITY TEST; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN TISSUE; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0030721974     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)00016-1     Document Type: Article

References (31)

1. Arbuck SG, Blaylock BA. Taxol: Clinical results and current issues in development. In: (Suffness M (ed.). Taxol - Science and applications. Boca Raton:CRC Press, 1995;379-415.
2. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72:2457-60.
3. Arbuck SG, Christian MC, Fisherman JS, et al. Clinical development of taxol. Natl Cancer Inst 1993;15:11-24.
4. ODAC prefers three-hour taxol infusion. The Cancer Letter 1993;19:38.
5. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30:444-50.
6. Horwitz SB. Taxol (paclitaxel): Mechanism of action. Annals Oncol 1994;5:53-6.
7. Crossin KL, Carney DH. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and epidermal growth factor. Cell 1981;27:341-50.
8. Liu Y, Bhalla K, Hill C, Priest DG. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 1994;48: 1265-72.
9. Bhalla K, Ilerado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-8.
10. Milas L, Hunter NR, Kurdoglu B. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995;35:297-303.
11. Li X, Gong J, Felman E, Seiter K, Traganos F, Darzynkiewicz Z. Apoptotic cell death during treatment of leukemias. Leuk Lymphoma 1994;13:65-70.
12. Gan Y, Wientjes MG, Schuller DE, Au JL-S. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 1996;56: 2086-93.
13. Vesico RA, Redfern CH, Nelson RJ, Ugoretz S, Stern PH, Hoffman RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 1987;84:5029-33.
14. Schroeder FH, Mackensen SJ. Human prostatic adenoma and carcinoma in cell culture-effects of androgen-free culture medium. Invest Urol 1974;12:176-81.
15. Mickey DD. Growth and differentiation factors in prostatic tissue. In: Motta M, Serio M (eds). Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects. Bussum, The Netherlands: Medicom, 1988;13-47.
16. Wientjes MG, Pretlow TG, Badalament RA, Burgers JK, Au JL-S. Histocultures of human prostate tissues for pharmacologic evaluation. J Urol 1995;153:1299-1302.
17. Robbins KT, Connors KM, Storniolo AM, Hanchett C, Huffman RM. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg 1994:120:288-92.
18. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1: 305-11.
19. Kubota T, Sasano N, Abe O, et al. and the Chemosensitivity Study Group for the Histoculture Drug-response Assay. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1995;l:1537-43.
20. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
21. Kerr JFR, Clay M, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
22. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994;71:219-25.
23. Dorr RT, Von Hoff DD. Paclitaxel. In: Cancer Chemotherapy Handbook, 2nd ed. Appleton & Lange: Norfolk, CT, 1994;761-7.
24. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-9.
25. Chen CT, Au JL-S, Burgers JK, Wientjes MG. Comparative activity of taxol and doxorubicin in human prostate tumors. Proc Am Assoc Cancer Res 1995;36:320.
26. Au JL-S, Kalns J, Can Y, Wientjes MG. Pharmacologic effects of taxol in human bladder tumors. J Urol 1996 (submitted).
27. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-42.
28. Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. The influence of Cremophor EL on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother Pharmacol 1994;33:331-9.
29. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987;8:1232-9.
30. Song D, Hsu L-F, Au JL-S. Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 1996;85:29-31.
31. Kang H-J, Tran A, Schuller DE, Au JL-S. Taxol uptake and retention in human cancer cells and solid tumors. Proc Am Assoc Cancer Res 1996;37:367.